NEOVACS
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoi... ds). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
NEOVACS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
1993-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.neovacs.fr
Total Employee:
11+
Status:
Active
Contact:
33 1 53 10 93 00
Email Addresses:
[email protected]
Total Funding:
44.79 M USD
Technology used in webpage:
IPv6 Pound Sterling Japanese Yen 1and1
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Piramed
Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alpha Blue Ocean™
Alpha Blue Ocean™ investment in Post-IPO Debt - Neovacs
Bpifrance
Bpifrance investment in Post-IPO Equity - Neovacs
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Neovacs
Truffle Capital
Truffle Capital investment in Venture Round - Neovacs
Debiopharm Innovation Fund
Debiopharm Innovation Fund investment in Venture Round - Neovacs
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-10-20 | Signia Therapeutics | Neovacs investment in Series A - Signia Therapeutics | 1.3 M EUR |
| 2021-09-27 | Bio-Detection K9 | Neovacs investment in Venture Round - Bio-Detection K9 | 5 M USD |
Official Site Inspections
http://www.neovacs.fr
- Host name: 217-160-0-99.elastic-ssl.ui-r.com
- IP address: 217.160.0.99
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Neovacs"
Accueil - Neovacs
May 15, 2020 · Nous avons deux types d'activités distinctes : une activité de Recherche et Développement et une activité d'investissement. Nous développons nos produits propres …See details»
Home - Neovacs
May 15, 2020 · Neovacs, a French Biotechnology company, develops products and invests in innovative companies (Biotech and Medtech)See details»
NEOVACS - LinkedIn
Neovacs, a French Biotechnology company, develops therapeutic vaccines for the treatment of autoimmune, inflammatory diseases aand invests in innovative companies (Biotech and Medtech).See details»
Neovacs - Crunchbase Company Profile & Funding
Neovacs, a biotech company, develops several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune and allergic diseases. Neovacs, a spin-off from the Pierre & Marie …See details»
NEOVACS: Shareholders Board Members Managers and Company …
6 days ago · NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates …See details»
Neovacs S.A. Company Profile | StatInvestor
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases. It focuses …See details»
Company Neovacs S.A. London S.E. - MarketScreener.com
May 27, 2003 · NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates …See details»
Accueil - Neovacs
May 15, 2020 · Back; Historique de la société; Back; Management; Back; Conseil d'AdministrationSee details»
Neovacs Company Profile - Office Locations, Competitors ... - Craft
Sep 26, 2024 · Neovacs is a French biotechnology company developing the next generation of therapeutic vaccines for autoimmune and inflammatory diseases and certain types of cancers. …See details»
Historique de la société - Neovacs
Fondée en 1993 comme spin-off de Paris Sorbonne (ex Université Pierre et Marie Curie), nous avons pour ambition de développer nos produits Kinoïde, issus de technologies brevetées, et …See details»
Neovacs S.A.: Actionnaires Dirigeants et Profil Société ...
NEOVACS est un acteur majeur dans les vaccins thérapeutiques ciblant le traitement des maladies auto-immunes et/ou inflammatoires. Ses produits propres sont des candidats …See details»
Présentation de la société NEOVACS : actionnariat, chiffres-clés et ...
Grâce à sa technologie innovante induisant une réponse immunitaire polyclonale, protégée potentiellement jusqu'en 2038 par 4 familles de brevets, NEOVACS concentre ses efforts de …See details»
Neovacs History - Neovacs
Founded in 1993 as a spin-off of Paris Sorbonne (formerly Pierre and Marie Curie University), our ambition is to develop our Kinoid products, resulting from patented technologies, and to invest …See details»
Néovacs et l’UTCBS unis pour un vaccin thérapeutique à ARN
L’entreprise Néovacs et l’Unité de technologies chimiques et biologiques pour la santé (UTCBS, CNRS/UPC/INSERM) ont signé un contrat de collaboration autour du développement de …See details»
Company NEOVACS Euronext Paris - MarketScreener.com
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own …See details»
Communiqué de la société NEOVACS du 27/05/2024 - Actusnews …
Suresnes, le 27 mai 2024 – 8h CET - Néovacs (Euronext Growth Paris : ALNEV) société biopharmaceutique à un stade préclinique développant de nouvelles thérapies pour des …See details»
Néovacs, cette biotech française qui veut vaincre le lupus - La …
Dec 7, 2016 · La biotech Néovacs a annoncé mercredi 7 décembre avoir obtenu auprès de l'agence américaine du médicament (FDA) la désignation de procédure accélérée (Fast …See details»
Management - Neovacs
Current Chairman and CEO of Neovacs, Hugo also exercises numerous mandates in different companies in France and around the world (ARCTURUS GROUP, BISTROTS PAS …See details»
NEOVACS : Néovacs dans le Top5 des avancées scientifiques selon …
Feb 26, 2024 · Néovacs est une société de biotechnologie française qui conduit une double activité de R&D et d’investissement. Ses produits propres sont des candidats vaccins …See details»
Neovacs - Communiqués
L'historique des publications est accessible depuis le mécanisme officiel français de stockage centralisé des informations réglementées www.info-financiere.fr.See details»